Biosensors posts 18% Q1 profit fall, sees more competition ahead
Revenue rises 5% but costs and expenses also go up
DeeperDive is a beta AI feature. Refer to full articles for the facts.
BIOSENSORS International Group yesterday posted an 18 per cent fall in its first-quarter net profit on higher costs and expenses.
The medical device manufacturer also warned of greater competition ahead.
"The management expects challenging market conditions such as increased competition and price erosion to continue in the global DES (drug-eluting stents) market," the company said in a regulatory filing. These devices are used to prevent reclogging of the arteries.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result